Clinical Trial Update: "Hepafast" in Non-alcoholic Fatty Liver Disease (NAFLD) [NA]

View source ↗

Summary

A clinical trial evaluating Hepafast for non-alcoholic fatty liver disease (NAFLD) with obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Obesity

Drugs mentioned

• Hepafast

Snippet

Sponsor: University of Hohenheim | Conditions: Non-alcoholic Fatty Liver Disease (NAFLD), Obesity | NA | Status: COMPLETED